This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Pediatrics, Other  • Alert me on articles by topic

Arch Pediatr Adolesc Med. 2005;159:196-197.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We greatly appreciated the article by King et al¹ for the thorough information that it gives about the pharmacologic treatment of bronchiolitis in infants. Nevertheless, we believe that in a systematic review about the pharmacologic treatment of bronchiolitis, surfactant should have been considered. Even if the interest for this treatment was limited to intubated children with very severe disease, these are the very children most in need of an efficacious therapy. There is convincing physiopathological evidence of the role played by surfactant’s genetics² and deficiency³ in the most severe forms of bronchiolitis. Furthermore, limited but repeated evidence from small clinical trials suggests that surfactant treatment is likely to be beneficial, playing a role in maintaining small-airway patency as well as lung compliance in children infected with respiratory syncytial virus.^4-5

After all, we believe that in the last 20 years a convincing body of evidence has been grown suggesting that routine . . . [Full Text of this Article]

AUTHOR INFORMATION

Egidio Barbi, MD; Elena Faleschini, MD; Stefania Bassanese, MD

RELATED ARTICLE

Do We Really Need More Trials About the Efficacy of Commonly Used Treatments for Bronchiolitis?—Reply
Valerie J. King, W. Clayton Bordley, and Meera Viswanathan
Arch Pediatr Adolesc Med. 2005;159(2):197.
EXTRACT | FULL TEXT